3.Yau T, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):e...
4. Yau T, Kang YK, KimTY, El-Khoueiry AB, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patientswith advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate040 randomized clinical ...
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial [published online ahead of print, 2022 Dec 13]. J Clin Oncol. 2022;JCO2200972. 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或...
1. El-Khoueiry, A.B., Sangro, B., Yau, T. et al. nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017. Jun 24;389(10088):2492-2502. 2. Hsu C., et al. nivo...
Bruno Sangro, MD, PhD, discusses the CheckMate-040 data and the future of immuno-oncology agents in HCC. Bruno Sangro, MD, PhD Data from the CheckMate-040 trial presented at the 2017 International Liver Congress showed promise for nivolumab (Opdivo) as a second-line therapy for patients with...
El-Khoueiry AB, Sangro B, Yau T,Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet.2017 Jun 24;389(10088):2492-2502. 专家简介: ...
The safety of nivolumab (PD-1 immune checkpoint inhibitor) was tested in a phase I/II, open-label, dose escalation and expansion trial (CheckMate 040), in patients with or without viral hepatitis and as first-line or second-line (after sorafenib) therapy....
5. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492–502.
Findings In the CheckMate 040 randomized clinical trial of nivolumab plus ipilimumab in patients with advanced hepatocellular cancer previously treated with sorafenib, patients were randomized 1:1:1 to 3 different treatment arms to evaluate different dosing regimens. Investigator-assessed objective response ...
5. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2doseescalation and expansion trial. Lancet 2017; 389: 2492–502. 6. Cainap C, Qin S, Huang WT, et al. Linifanib versus...